Multi-disciplinary proactive follow-up algorithm for patients with advanced NSCLC receiving afatinib

Authors:

Abstract
Afatinib is a standard first-line therapy for advanced EGFR-positive NSCLC. We implemented a pharmacist-led proactive follow-up algorithm to identify and manage early afatinib-related adverse events (AEs).
Funding Information
  • Boehringer Ingelheim

This publication has 33 references indexed in Scilit: